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Introduction: Unlike unipolar depression, depressive episode of bipolar disorder is often 
associated with clinical characteristics, such as atypical and mixed symptoms. However, 
there are currently no valid and reliable specific tools available to assess the specific 
psychiatric symptomatology of depressive episode of bipolar disorder in China. Therefore, 
we aimed to evaluate the psychometric properties of the Chinese version of the Bipolar 
Depression Rating Scale (BDRS) in Chinese patients with bipolar disorder.
Methods: The sample of this study included 111 patients with bipolar disorder (30 male, 81 
female). All participants were interviewed with the Chinese version of the BDRS (BDRS-C), 
the 17-item Hamilton Depression Rating Scale (HAMD-17), the Montgomery-Asberg 
Depression Rating Scale (MADRS) and the Young Mania Rating Scale (YMRS). 
A psychometric analysis of the BDRS was conducted.
Results: The Cronbach’s alpha coefficient of the BDRS-C reached a value of 0.869. The 
BDRS-C score and scores for the HAMD-17 (r = 0.819, p < 0.01), the MADRS (r = 0.882, 
p < 0.01) and the YMRS (r = 0.355, p < 0.01) exhibited significant positive correlations. 
Close correlations were observed between the mixed subscale score of the BDRS-C and the 
YMRS score (r = 0.784, p < 0.01). Exploratory factor analysis resulted in three factors: 
a primary depressive symptoms cluster, a secondary depressive symptoms cluster, and 
a mixed symptoms cluster.
Conclusion: The Chinese version of the BDRS has satisfactory psychometric properties. This 
is a valid and reliable instrument to assess depressive symptomatology in patients with bipolar 
disorder.
Keywords: bipolar disorder, mania, depression, psychometrics, depressive episode, rating 
scale, psychiatry
Introduction
Bipolar disorder is characterized by recurrent episodes of depression that are typically 
interspersed with manic or hypomanic symptoms. It accounts for a large proportion of 
the global burden of disease and is thus a major public health concern.1 A worldwide 
meta-analysis showed that the lifetime prevalence of bipolar disorder was over 2% in 
the general adult population,2 higher than the corresponding figures in China.3,4 
Depressive symptoms rather than (hypo)manic symptoms represent the predominant 
abnormal mood state for patients with both bipolar I and II disorders.5–7 The clinical 
significance of depressive episode of bipolar disorder is underscored by a strong 
association with a markedly increased risk of suicide.8–10 It is recommended that 
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clinicians routinely assess depressive symptoms in patients 
suffering from bipolar disorder.10
Making an accurate diagnosis of bipolar disorder is diffi-
cult in clinical practice because approximately half of the 
patients present with depression as their first episode, and 
depressive episode of bipolar disorder and unipolar depression 
share similar symptoms.11,12 Therefore, it is particularly criti-
cal to reveal the distinction between bipolar and unipolar 
depression, which can help to identify unipolar depression. 
Recently, some studies confirmed that many of the character-
istic symptoms were associated with a depressive episode of 
bipolar disorder, such as depression with a few manic symp-
toms (depressive mixed state), psychotic depression, atypical 
depression and mood lability.13–17 In the Diagnostic and 
Statistical Manual of Mental Disorders Fifth Edition (DSM- 
5),18 atypical depression is characterized by an increase in 
appetite, hypersomnia, leaden paralysis, and a long-standing 
pattern of interpersonal relationship sensitivity. Clinical psy-
chiatric evaluations optimized for unipolar depression, such as 
the Montgomery and Asberg Depression Scale (MADRS)19 
and the 17-item Hamilton Depression Scale (HAMD-17),20 
have been widely used among patients with a depressive 
episode of bipolar disorder. However, these tools do not 
include many symptoms specific to depressive episode of 
bipolar disorder, such as atypical and mixed features.21,22 
Thus, utilizing these scales for patients with a depressive 
episode of bipolar disorder could be misleading in both clinical 
research studies and clinical practice. Improved understanding 
of the psychopathological characteristics of bipolar depression 
and the development of good assessment tools are critical.
A new assessment tool scale called the Bipolar Depression 
Rating Scale (BDRS), which is the first semi-structured, clin-
ician-rated scale tailored to the symptom profile of depressive 
episode of bipolar disorder, was established and validated in 
2007 by Berk et al.21 The BDRS comprises 20 items that are 
individually evaluated from 0 to 3 and can be divided into two 
subscales: the depressive subscale and the mixed subscale. In 
this scale, atypical symptoms such as hypersomnia and hyper-
phagia, as well as mixed symptoms (eg, increased speech, 
increased motor drive and agitation), are included.21 It is 
a useful tool not only for assessing depressive symptomatology 
but also for evaluating the effectiveness of the intervention in 
the management of depressive episode of bipolar disorder.23–27
The BDRS was originally written in English and has so far 
been successfully translated into approximately 5 languages, 
including Iranian,28 Turkish,29 Spanish,30 Korean31,32 and 
Italian.33 All versions of the BDRS were demonstrated to be 
valid and reliable tools. As such, the purposes of our study were 
to translate the English version of the BDRS into Chinese with 
appropriate cultural adaptation and investigate the reliability and 
validity of the Chinese version of the BDRS (BDRS-C) for the 
evaluation of patients with bipolar disorder in China.
Methods
Participants
This study was conducted between February 1, 2019, and 
December 31, 2019, in Beijing Hui-Long-Guan Hospital, 
Beijing, China. Participants were recruited from patients suffering 
from bipolar disorder through convenience sampling. For reliabil-
ity and validity testing and factor analysis, the sample size should 
be 5–10 times the number of items in the scale and should be >100 
participants. In addition, according to the sample size in studies 
about other language versions of the scale,21,28–33 we set the 
sample size to 120. Inclusion criteria included subjects with the 
following characteristics: age between 18 and 65 years old and 
meeting the DSM-5 for bipolar disorder by the consensus of two 
independent senior psychiatrists with the title of an associate chief 
physician or above. All participants were Chinese. Patients were 
excluded if they had severe cognitive impairment.
The study protocol was approved by the Human Ethics 
Committee of Beijing Hui-Long-Guan Hospital, and all sub-
jects provided written informed consent according to the 
Declaration of Helsinki.
Procedure
The original BDRS is an interview-based tool. This scale 
contains 20 items, with each item rated on a 4-point Likert 
scale (0 = nil, 1 = mild, 2 = moderate, and 3 = severe) based on 
a manual that includes the description of the characteristics of 
every item.21 The total score ranges from 0 to 60, with higher 
scores indicating more severe depression. This scale contains 
three factors, namely, depression (somatic), depression (psy-
chological) and mixed symptom clusters. The BDRS demon-
strated excellent internal consistency (Cronbach’s α=0.917).21
Four steps were undertaken to achieve a high-quality Chinese 
translation and comparability with the original scale. First, two 
clinical psychiatrists (Yin L and Yang KB) fluent in English and 
Chinese independently translated the original scale into Chinese 
and developed two translation versions. Then, both translations 
were integrated by the translators into a single version by discus-
sion. Next, the expert panel (Su YA, Chen JX) revised and 
modified inconsistent and inaccurate items to obtain the final 
Chinese version of the BDRS. The expressions of all items were 
simple and easy to understand and were adapted culturally at 
a conceptual level across Chinese cultures. The final version was 
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back-translated into English by Li BB, who had not read the 
original version of the BDRS, followed by a consistency check 
by the corresponding author of the original publication.21 The 
evaluators determined that there were no phenomena that were 
difficult for the participants to understand.
All investigators participating in this study were experienced 
psychiatrists with more than 10 years of clinical experience in the 
field of affective disorders. Four of them assessed all participants 
by the BDRS-C, the MADRS, the HAMD-17 and the Young 
Mania Rating Scale (YMRS).34 The four raters were trained in 
a whole-day session with a discussion of each scale and training 
on cases until the internal concordance reached a value of at 
least 0.80.
The interrater reliability of the BDRS-C was established 
on the basis of ratings of 35 patients who were randomly 
selected from all the participants by the four raters. Each 
rater performed an independent evaluation using the BDRS- 
C scale manual without communication, and one senior phy-
sician performed a clinical psychiatric examination on these 
patients. Thirty-six patients were randomly selected and 
assessed twice by the same assessor for the BDRS-C intra- 
rater and inter-rater reliability tests at a 5-day interval.
Data Analysis
To measure the internal consistency of the scale, we 
used Cronbach’s α coefficient defined as follows: 
>0.90: excellent, 0.8–0.9: good, 0.7–0.8: acceptable, 
0.6–0.7: questionable, 0.5–0.6: poor, <0.5: 
unacceptable.32 To measure the interrater and intrarater 
reliability, we computed intraclass correlation coeffi-
cients (ICC) with 95% confidence intervals. Concurrent 
validity was measured by Pearson’s correlation to exam-
ine the relationships between the scores of the BDRS-C 
and the other scales (HAMD-17, MADRS and YMRS). 
Furthermore, a factor analysis was performed to identify 
the underlying dimensions and structure of the BDRS-C. 
The factors were determined using the method of 
unweighted least squares with varimax factor rotations 
and a scree plot. All statistical tests were two-tailed, and 
statistical significance was achieved when p < 0.05. 
Data were analyzed using SPSS Statistical Package (ver-
sion 20.0) for Windows.
Results
A total of 120 patients with bipolar disorder participated in the 
study. However, nine of them had more than 10% missing data 
(more than two missing items) in the BDRS-C and were 
excluded from further analyses. Among all 111 participants, 
the average age was 32.2±13.5 years old, and 81 were female 
(73.0%). The sample consisted of 6 patients with hypo/manic 
episodes (5.4%), 80 patients with depressive episodes (73.9%), 
14 patients with mixed episodes (12.6%) and 11 euthymic 
patients (9.9%). Of these patients, 88 met the criteria for bipolar 
Table 1 Sociodemographic and Clinical Characteristics of the 
Sample (n=111)
Variables Values




Employed (n, %) 63 (59.4%)
Marital status (n, %)
Never married 37 (33.3%)
Married 65 (58.6%)
Divorced 9 (8.1%)
Educational level (n, %)
Up to 6 years 17 (15.3%)
7–12 years 35 (31.5%)
13–16 years 52 (46.8%)
Over 16 years 7 (6.3%)
Onset age (years, mean ± SD) 23.6 ± 9.4
Duration of illness (Months, median, IQR) 77 (132)
Diagnosis
Bipolar I disorder 88 (79.3%)
Bipolar II disorder 23 (20.7%)
Mood state (n, %)
Hypo/manic episode 6 (5.4%)
Euthymic 11 (9.9%)
Depressive episode 80 (73.9%)
Mixed episode 14 (12.6%)
Medication (n, %)
MS + AP 20 (18.0%)
MS + AD 15 (13.5%)
AP + AD 9 (8.1%)
MS + AP + AD 63 (56.8%)
AP monotherapy 3 (2.7%)
MS monotherapy 1 (0.9%)
Scales scores
BDRS score (mean ± SD) 24.1 ± 10.04
HAMD score (median, IQR) 16 (13)
MADRS score (median, IQR) 22 (18)
YMRS score (median, IQR) 3 (8)
Abbreviations: SD, standard deviation; IQR, interquartile range; SSRI, selective 
serotonin reuptake inhibitors; HAMD, Hamilton Depression Scale; MADRS, 
Montgomery and Asberg Depression Scale; YMRS, Young Mania Rating Scale; MS, 
mood stabilizer; AP, antipsychotic; AD, antidepressant.
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I disorder (79.3%) and 23 met the criteria for bipolar II disorder 
(20.7%). Relevant sociodemographic and clinical data for the 
subjects are summarized in Table 1.
Table 2 shows the internal consistency of the BDRS-C. 
Internal consistency was good, with an overall Cronbach’s 
α coefficient of 0.869. Good internal consistency was also 
found in the depressive subscale of the BDRS-C (items 
1–15), with Cronbach’s α coefficient up to 0.891. In 
comparison, the mixed subscale (items 16–20) had 
a lower Cronbach’s α coefficient of 0.730 but was 
acceptable.
As shown in Table 3, Pearson’s correlation coefficients 
between the BDRS-C score and the HAMD-17, MADRS 
and YMRS scores were identified. The BDRS-C scores 
were highly associated with the HAMD-17 scores (r = 
0.866, p < 0.01) as well as the MADRS scores (r = 
Table 2 Internal Consistency Features of the Chinese Version of the BDRS (n=111)
Mean Value if Item 
Deleted




Cronbach’s α if Item 
Deleted
1.Depression 22.09 89.010 0.653 0.857
2.Sleep disturbance 22.38 88.819 0.502 0.862
3.Appetite disturbance 22.72 88.421 0.494 0.862
4.Social impairment 22.36 87.687 0.569 0.859
5.Activity/energy 
reduction
22.27 88.199 0.613 0.858
6.Reduced motivation 22.32 87.676 0.610 0.858
7.Reduced 
concentration
22.27 89.708 0.508 0.862
8.Anxiety 22.45 88.159 0.555 0.860
9.Anhedonia 22.39 87.749 0.571 0.859
10.Flattened affect 22.95 90.415 0.466 0.863
11.Worthlessness 22.44 85.940 0.586 0.858
12.Helplessness 22.56 86.849 0.623 0.857
13.Suicidal ideation 23.06 88.732 0.520 0.861
14.Guilt 22.45 90.159 0.465 0.863
15.Psychotic symptoms 22.94 91.223 0.422 0.865
16.Irritability 22.96 93.799 0.373 0.866
17.Lability 22.99 92.209 0.376 0.866
18.Increased motor 
drive
23.55 100.468 −0.094 0.878
19.Increased speech 23.50 99.161 0.000 0.876





Abbreviations: BDRS-C, Bipolar Depression Rating Scale; BDRS-D, the depressive subscale of BDRS-C; BDRS-M, the mixed subscale of BDRS-C.
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0.819, p < 0.01) but weakly correlated with the scores of 
the YMRS (r = 0.355, p < 0.01). Further analysis showed 
that the associations between the scores for the depressive 
subscale of the BDRS-C and the HAMD-17 and MADRS 
scores were strongly correlated (r = 0.834, p < 0.01; r = 
0.906, p < 0.01; respectively). Pearson correlation coeffi-
cients demonstrated high correlations between the scores 
for the mixed subscale of the BDRS-C and the YMRS 
scores (r = 0.784, p < 0.01).
The results showed that the Kaiser-Meyer-Olkin 
(KMO) value, which was calculated as an indicator of 
data coherence, was 0.824, and Bartlett’s test of sphericity 
reached a level of significance (χ2 = 876.202, p < 0.01), 
indicating that it was suitable for exploratory factor ana-
lysis. An unweighted least squares factor analysis was 
performed, followed by oblique (Promax) rotations of 
2–5 factors. Prior to rotation, the five eigenvalues above 
1 were 6.332, 2.642, 1.393, 1.162 and 1.062, with corre-
sponding percentages of variance accounted for of 
31.660%, 13.210%, 6.965%, 5.812% and 5.309%. Based 
on examination of a scree plot and other international 
versions of BDRS,21,29–31,33 the three-factor solution 
with an oblique rotation was judged to provide a useful 
account of the data which explained 51.835% of the total 
variance. Table 4 shows the component loading matrix 
(only loads >0.30), eigenvalues and percent of variance 
accounted for each factor. The first factor was named the 
primary depressive symptoms cluster (Factor 1) because it 
concerned aspects such as depression, activity/energy 
reduction, reduced motivation, anhedonia, and suicidal 
ideation. The second factor was labeled the secondary 
depressive symptoms cluster (Factor 2) because it con-
cerned aspects such as social impairment, anxiety, guilt, 
and psychotic symptoms. The last factor was labeled the 
mixed symptoms cluster because it concerned manic/ 
hypomanic aspects, for example, lability, increased 
motor drive, increased speech or agitation. The primary 
and secondary depressive symptom clusters also formed 
a composite depressive symptom cluster.
The inter-rater reliability for the four physicians across 
a subgroup of 35 (31.5%) of 111 participants was assessed 
using ICC. As shown in Table 5, the inter-rater reliability 
was high, yielding an ICC of 0.946 (95% confidence 
interval [CI] 0.912–0.970); this was also the case for the 
depressive factor (ICC: 0.961; 95% CI: 0.936–0.978) and 
the mixed factor (ICC: 0.799; 95% CI: 0.694–0.881). The 
results also demonstrated that each item had moderate to 
high inter-rater reliability, except for item 17 (lability).
Test–retest reliability was performed in the subgroup of 
36 participants at five-day intervals (Table 6). The ICC 
was 0.930 for the total score (95% CI: 0.880–0.967), 0.955 
for the depressive factor (95% CI: 0.921–0.979) and 0.791 
for the mixed factor (95% CI: 0.619–0.915). Intra-rater 
reliability for this assessment was moderate to high for 
individual items (ICC = 0.632–0.901).
Table 3 Correlations Between the Total Scores of the BDRS, HDRS, MADRS, YMRS and Factors (n=111)
YMRS HAMD MADRS BDRS BDRS-D BDRS-M Factor1 Factor2 Factor3
YMRS 1
HAMD 0.254** 1
MADRS 0.122 0.882** 1
BDRS 0.355** 0.819** 0.866** 1
BDRS-C-D 0.168 0.834** 0.906** 0.967** 1
BDRS-C-M 0.784** 0.145 0.068 0.368** 0.123 1
Factor1 0.161 0.803** 0.875** 0.947** 0.974** 0.135 1
Factor2 0.199* 0.725** 0.748** 0.810** 0.816** 0.175 0.722** 1
Factor3 0.784** 0.145 0.068 0.368** 0.123 1.000** 0.080 0.175 1
Notes: Factor1: primary depressive symptoms cluster. Factor2: secondary depressive symptoms cluster. Factor3: mixed symptoms cluster. *Correlation is significant at the 
0.05 level. **Correlation is significant at the 0.01 level. 
Abbreviations: YMRS, Young Mania Rating Scale; HAMD, Hamilton Depression Scale; MADRS, Montgomery Asberg Depression Rating Scale; BDRS, Bipolar Depression 
Rating Scale; BDRS-C-D, the depressive subscale of the BDRS-C; BDRS-C-M, the mixed subscale of Bipolar Depression Rating Scale.
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Discussion
To our knowledge, this is the first study to translate 
and evaluate the psychometric properties of a scale for 
evaluating the severity of bipolar depressive symptoms 
in the Chinese population. The Cronbach’s alpha ana-
lysis suggests good internal consistency of this instru-
ment (α = 0.869). Although the BDRS-C in the patients 
with bipolar disorder was somewhat lower in compar-
ison with the original BDRS (α = 0.917),21 the internal 
consistency is consistent with other validation studies 
in different sociocultural contexts. For example, 
Cronbach’s alpha was found to be 0.81 in the Iranian 
version,28 0.870 in the Spanish version,30 0.866 in the 
Korean version,31 and 0.82 in the Italian version.33 
Therefore, the results we obtained showed that the 
BDRS-C is a valid and reliable instrument for measur-
ing the severity of depression in Chinese patients with 
bipolar disorder. Moreover, the four raters’ agreements 
concerning each item score ranged from 0.544 to 
0.917, which indicates acceptable reliability of the rat-
ing of different items.
Table 4 Factor Analysis of the Chinese Version of the BPRS (n=111)




4.Social impairment 0.504 0.517













18.Increased motor drive 0.671
19.Increased speech 0.764
20.Agitation 0.732
Notes: Extraction Method: Unweighted Least Squares. Rotation Method: Varimax 
with Kaiser Normalization. Factor1: primary depressive symptoms cluster. Factor2: 
secondary depressive symptoms cluster. Factor3: mixed symptoms cluster. 
Abbreviation: BDRS, Bipolar Depression Rating Scale.
Table 5 Inter-Rater Reliability (n=35)
ICC (95% CI) p
1.Depression 0.737 0.611–0.841 <0.001
2.Sleep disturbance 0.766 0.650–0.860 <0.001
3. Appetite disturbance 0.817 0.719–0.892 <0.001
4.Social impairment 0.814 0.716–0.891 <0.001
5.Activity/energy reduction 0.774 0.660–0.865 <0.001
6.Reduced motivation 0.827 0.733–0.898 <0.001
7.Reduced concentration 0.904 0.846–0.945 <0.001
8.Anxiety 0.917 0.866–0.953 <0.001
9.Anhedonia 0.924 0.877–0.957 <0.001
10.Flattened affect 0.800 0.696–0.882 <0.001
11.Worthlessness 0.880 0.811–0.931 <0.001
12.Helplessness 0.903 0.845–0.945 <0.001
13.Suicidal ideation 0.928 0.883–0.959 <0.001
14.Guilt 0.796 0.689–0.879 <0.001
15.Psychotic symptoms 0.887 0.821–0.936 <0.001
16.Irritability 0.706 0.571–0.820 <0.001
17.Lability 0.544 0.379–0.704 <0.001
18.Increased motor drive 0.705 0.569–0.819 <0.001
19.Increased speech 0.716 0.583–0.827 <0.001
20.Agitation 0.839 0.750–0.906 <0.001
BDRS total score 0.946 0.912–0.970 <0.001
BDRS-D 0.961 0.936–0.978 <0.001
BDRS-M (items16–20) 0.799 0.694–0.881 <0.001
Abbreviations: BDRS, Bipolar Depression Rating Scale; BDRS-D, the depressive 
subscale of the BDRS (items1–15); BDRS-M, the mixed subscale of Bipolar 
Depression Rating Scale.
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We investigated the concurrent validity of the 
BDRS-C by computing Pearson correlation coefficients 
with other validated scales. In line with the previous 
findings, our data demonstrated that both the total 
BDRS-C scores and the depressive subscale scores 
had a strong positive correlation with the HAMD-17 
and the MADRS scores. These results indicate that the 
scale performs equally well as the HAMD-17 and 
MADRS in accurately assessing depressive symptoma-
tology in patients suffering from a depressive episode 
of bipolar disorder. In addition to evaluating 
depression, the BDRS-C assesses mixed symptoms of 
depressive episode of bipolar disorder, such as 
increased motor drive and speech. A moderate correla-
tion was found when the mixed subscale was compared 
with the YMRS, as expected. This finding is very 
important since many patients suffering from 
a depressive episode of bipolar disorder have concur-
rent manic symptoms that must be evaluated, and the 
BDRS was designed to capture these clinical features.
Factor analysis confirmed that the three-factor 
structure of the BDRS-C is consistent with the con-
struction of the original and other international valida-
tions, but the labels of the three factors and several 
items were different. In the original scale, the factors 
were loaded onto psychological depression (eg, social 
impairment, anxiety, anhedonia, worthlessness, help-
lessness), somatic depression (eg, depression, sleep 
and appetite disturbance, reduced motivation and con-
centration), and mixed factors (eg, psychotic symp-
toms, lability, and increased motor drive and 
speech).21 However, in our study, depression, sleep 
disturbance, appetite disturbance, activity/energy 
reduction, reduced motivation, anhedonia, flattened 
affect, worthlessness, helplessness, and suicidal idea-
tion were classified as primary depressive factors. Most 
of these items are symptomatic diagnostic criteria of 
major depressive episodes from the DSM-5 and the 
International Classification of Diseases (ICD-11). 
Social impairment, reduced concentration, anxiety, 
guilt, and psychotic symptoms were grouped under 
the secondary depressive factor because they did not 
constitute the core symptoms of depression. The differ-
ences in depressive factors between our study and the 
original study21 may be associated with the clinical 
characteristics of the patients in two studies and cul-
tural differences. It is well documented that depression 
symptom patterns are influenced by ethnocultural 
backgrounds.35 For Chinese patients, they tend to 
express more somatic symptoms.36 Consistently, the 
factor analysis in our study has shown that both the 
items including the core symptoms and somatic symp-
toms of depression have loaded onto the same factor 
(primary depressive factor). The items in the mixed 
factor included irritability, lability, motor drive and 
increased speech, and agitation and were the same as 
the Spanish validation30 and the Korean version;31,32 
Table 6 Intra-Rater Reliability (n=36)
ICC (95% CI) p
1.Depression 0.771 0.650–0.861 <0.001
2.Sleep disturbance 0.849 0.745–0.826 <0.001
3.Appetite disturbance 0.713 0.514–0.839 <0.001
4.Social impairment 0.858 0.756–0.929 <0.001
5.Activity/energy reduction 0.802 0.693–0.886 <0.001
6.Reduced motivation 0.901 0.803–0.957 <0.001
7.Reduced concentration 0.761 0.564–0.887 <0.001
8.Anxiety 0.829 0.717–0.919 <0.001
9.Anhedonia 0.881 0.796–0.943 <0.001
10.Flattened affect 0.875 0.773–0.951 <0.001
11.Worthlessness 0.854 0.729–0.944 <0.001
12.Helplessness 0.825 0.680–0.933 <0.001
13.Suicidal ideation 0.705 0.452–0.898 <0.001
14.Guilt 0.667 0.441–0.835 <0.001
15.Psychotic symptoms 0.873 0.727–0.950 <0.001
16.Irritability 0.715 0.461–0.876 <0.001
17.Lability 0.632 0.289–0.895 <0.001
18.Increased motor drive 0.800 0.527–0.961 <0.001
19.Increased speech 0.840 0.673–0.943 <0.001
20.Agitation 0.689 0.360–0.931 <0.001
BDRS 0.930 0.880–0.967 <0.001
BDRS-D 0.955 0.921–0.979 <0.001
BDRS-M 0.791 0.619–0.915 <0.001
Abbreviations: BDRS, Bipolar Depression Rating Scale; BDRS-D, the depressive 
subscale of the BDRS (items1–15); BDRS-M, the mixed subscale of Bipolar 
Depression Rating Scale.
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however, this was not the case in the original study, 
which included psychotic symptoms but did not include 
irritability.21
In this study, test–retest reliability was used to evalu-
ate score stability within a five-day interval. The test– 
retest reliability of the total BDRS-C and the depressive 
subscale was excellent, and the mixed subscale was 
acceptable. The same analysis showed that the test–retest 
reliability of each item was acceptable except for three 
items (guilt, lability and agitation) with relatively low 
reliability.
This study presents limitations that need to be taken 
into account. First, the convenience sampling method was 
adopted, and the participants were all from one hospital. 
Therefore, the BDRS-C should be further verified in multi-
ple regions. Second, we did not conduct structured diag-
nostic interviews to determine the diagnosis. Finally, all 
patients were on psychotropic medication at the time of 
the interviews, which may have impacted the item ratings.
In summary, our findings provide sufficient evidence 
of the validity of the BDRS-C. Consistent with the 
original scale, the BDRS-C presents satisfactory psycho-
metric properties with good internal validity, interrater 
reliability and strong correlations with other commonly 
used depression rating scales. Therefore, it can be used 
in clinical practice and medical research, including eva-
luation of the clinical efficacy of new drugs, as a valid 
measurement instrument and a specific tool to screen 
and quantify the severity of depressive episode of bipo-
lar disorder.
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